The primary objective in Phase I is to evaluate the safety and tolerability of ESG401 as a
single agent administered in 21-day treatment cycles in previously treated participants with
advanced epithelial cancer. In Phase II, the primary objective is to evaluate the safety and
efficacy of ESG401 administered in 21-day treatment cycles at a dose selected in Phase I.
Tumor types in the study will include: cervical, colorectal, endometrial, ovarian,
esophageal, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous
cell, hepatocellular, prostate, non-small-cell lung cancer, pancreatic, renal cell,
small-cell lung cancer, non-triple negative breast cancer (non-TNBC), triple-negative breast
cancer (TNBC) and metastatic urothelial cancer (mUC).